Last reviewed · How we verify

Subcutaneous Fluid Administration for Achieving Hydration — Treatment Landscape & Competitive Intelligence

Subcutaneous Fluid Administration for Achieving Hydration (disease) competitive landscape: 1 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

1 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Subcutaneous Fluid Administration for Achieving Hydration, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Recombinant antithrombin (rhAT) Recombinant antithrombin (rhAT) Mayo Clinic Dispersion agent; enzyme Hyaluronic acid and connective tissue polysaccharides

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Mayo Clinic · 1 drug in Subcutaneous Fluid Administration for Achieving Hydration

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Subcutaneous Fluid Administration for Achieving Hydration:

Cite this brief

Drug Landscape (2026). Subcutaneous Fluid Administration for Achieving Hydration — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/subcutaneous-fluid-administration-for-achieving-hydration. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing